Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and pazopanib

lestaurtinib has been researched along with pazopanib in 3 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(pazopanib)		Trials
(pazopanib)		Recent Studies (post-2010) (pazopanib)
12412631,1472371,028

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)pazopanib (IC50)
Multidrug resistance-associated protein 4Homo sapiens (human)8.1
Tyrosine-protein kinase ABL1Homo sapiens (human)2.2043
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.21
Cytochrome P450 3A4Homo sapiens (human)0.03
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0837
Cytochrome P450 2D6Homo sapiens (human)0.03
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0887
Fibroblast growth factor receptor 1Homo sapiens (human)0.1477
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.071
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.032
Fibroblast growth factor receptor 2Homo sapiens (human)0.14
AcetylcholinesteraseHomo sapiens (human)0.93
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0467
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.4929
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.873
Discoidin domain-containing receptor 2Homo sapiens (human)0.0505
Receptor protein-tyrosine kinase Homo sapiens (human)2.2043

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Dewhurst, S; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Marker, DF; Nguyen, T; Polesskaya, O; Pollack, S; Ravula, SB; Sheppard, D; Todd, DE; Wiemann, T; Xu, Y1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

3 other study(ies) available for lestaurtinib and pazopanib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
    Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20

    Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Carbazoles; Cells, Cultured; Cognition Disorders; Drug Discovery; HIV Infections; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinase Kinase 11; Models, Chemical; Molecular Structure; Monocytes; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; Tumor Necrosis Factor-alpha

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017